*By Bridgette Webb* Real estate start-up EasyKnock recently closed a $3.5 million dollar funding round. Founder and CEO Jarred Kessler said Monday in an interview on Cheddar knows what he'll do with that cash. "We are looking to increase our marketing and our head count and our technology offerings," Kessler said. The company is also planning to partner with mortgage lenders to pay a referral fee for rejected customers. EasyKnock buys homes and leases them back to the previous owner at the market rate. That way, a customer can refinance or liquidate, and the company has a reliable tenant ー and a source of revenue. The homeowner maintains the option to purchase his or her home back. The company currently operates in five states: Texas, Georgia, Florida, Tennessee, and South Carolina. For full interview [click here](https://cheddar.com/videos/easyknock-lands-3-5-million).

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More